Inhibitors of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MK2) as Treatment for Inflammatory Diseases.

The invention in this patent application relates to 9,10,11,12-tetrahydro-8 H -[1,4]diazepino[5',6':4,5]thieno[3,2- f ]quinolin-8-one derivatives represented herein generally by Formula 1 . These compounds are inhibitors of MK2 kinases and may provide useful treatments for MK2-mediated diseases or disorders such as autoimmune disorders, chronic or acute inflammatory disorders, autoinflammatory disorders, fibrotic disorders, metabolic disorders, neoplasia, or cardiovascular or cerebrovascular disorders.